{"protocolSection": {"identificationModule": {"nctId": "NCT00556673", "orgStudyIdInfo": {"id": "CQMF149A2204"}, "secondaryIdInfos": [{"id": "2007-002360-10", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler\u00ae Device in Adult Patients With Asthma", "officialTitle": "An Exploratory, Multi-centre, Double-blind, Placebocontrolled Crossover Study, to Investigate the Bronchodilatory Efficacy of a Single Dose of Indacaterol in Fixed Combination With Mometasone Furoate Delivered Via a MDDPI (Twisthaler\u00ae) in Adult Patients With Persistent Asthma Using Open Label Seretide\u00ae Accuhaler\u00ae (50/250 Mcg b.i.d.) as an Active Control"}, "statusModule": {"statusVerifiedDate": "2013-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-10"}, "primaryCompletionDateStruct": {"date": "2008-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-11-09", "studyFirstSubmitQcDate": "2007-11-09", "studyFirstPostDateStruct": {"date": "2007-11-12", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-03-11", "resultsFirstSubmitQcDate": "2013-03-11", "resultsFirstPostDateStruct": {"date": "2013-04-22", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-03-11", "lastUpdatePostDateStruct": {"date": "2013-04-22", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}, "collaborators": [{"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study is designed to evaluate the bronchodilatory efficacy of indacaterol maleate 500 \u03bcg/mometasone furoate 400 \u03bcg via the Twisthaler\u00ae device in adult patients with persistent asthma."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma, QMF149, fixed combination of indacaterol and mometasone furoate"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 31, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Indacaterol/mometasone - Placebo", "type": "EXPERIMENTAL", "description": "In Treatment Period 1 (Day 1) participants received 2 inhalations of indacaterol maleate 250 \u03bcg / mometasone furoate 200 \u03bcg once a day in the morning via the Twisthaler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of placebo via the Twisthaler device once a day in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 \u03bcg / salmeterol xinafoate 50 \u03bcg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days.", "interventionNames": ["Drug: indacaterol maleate/mometasone furoate", "Drug: placebo to indacaterol maleate/mometasone furoate", "Drug: fluticasone proprionate / salmeterol xinafoate"]}, {"label": "Placebo - indacaterol/mometasone", "type": "EXPERIMENTAL", "description": "In Treatment Period 1 (Day 1) participants received 2 inhalations of placebo in the morning via the Twistheler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of indacaterol maleate 250 \u03bcg / mometasone furoate 200 \u03bcg via the Twisthaler device in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 \u03bcg / salmeterol xinafoate 50 \u03bcg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days.", "interventionNames": ["Drug: indacaterol maleate/mometasone furoate", "Drug: placebo to indacaterol maleate/mometasone furoate", "Drug: fluticasone proprionate / salmeterol xinafoate"]}], "interventions": [{"type": "DRUG", "name": "indacaterol maleate/mometasone furoate", "description": "Indacaterol maleate 250 \u03bcg / mometasone furoate 200 \u03bcg delivered via the Twisthaler device.", "armGroupLabels": ["Indacaterol/mometasone - Placebo", "Placebo - indacaterol/mometasone"], "otherNames": ["QMF149"]}, {"type": "DRUG", "name": "placebo to indacaterol maleate/mometasone furoate", "description": "Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.", "armGroupLabels": ["Indacaterol/mometasone - Placebo", "Placebo - indacaterol/mometasone"]}, {"type": "DRUG", "name": "fluticasone proprionate / salmeterol xinafoate", "description": "Fluticasone proprionate 250 \u03bcg / salmeterol xinafoate 50 \u03bcg delivered via the Accuhaler\u00ae device.", "armGroupLabels": ["Indacaterol/mometasone - Placebo", "Placebo - indacaterol/mometasone"], "otherNames": ["Seretide\u00ae Accuhaler\u00ae"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Period Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)", "description": "FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Change from the period baseline to 24 hour post dose trough FEV1 after 1 day of treatment was modeled using a linear mixed effect model fitting treatment, sequence and period as fixed factors, patient within sequence as a random factor and pre-dose FEV1 as covariate.", "timeFrame": "Pre-dose for each Treatment Period (Days 1, 8 and 15) and 24-hours post-dose for each Treatment Period (Days 2, 9 and 16)."}], "secondaryOutcomes": [{"measure": "Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)", "description": "FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Peak FEV1 is defined as the peak FEV1 between 0 and 4 hours post-dose. The change from baseline in peak FEV1 was modeled using a linear mixed effect model fitting treatment, sequence and period as fixed factors, patient within sequence as a random factor and pre-dose FEV1 as covariate.", "timeFrame": "Days 1, 8 and 15, pre-dose (Baseline) and 5, 15, and 30 minutes, 1, 2, 3, and 4 hours post-dose."}, {"measure": "Change From Period Baseline in Trough Percent Predicted Forced Expiratory Volume in 1 Second (FEV1)", "description": "Trough FEV1 was measured 24 hours post-dose. The FEV1 percent predicted expresses FEV1 as a percentage of the \"predicted values\" for participants of similar characteristics (height, age, sex, and sometimes race and weight). A positive change from baseline in FEV1 % predicted indicates improvement in lung function. Change from baseline in trough FEV1 % predicted was modeled using a linear mixed effect model fitting treatment, sequence and period as fixed factors, patient within sequence as a random factor and pre-dose value as covariate.", "timeFrame": "Pre-dose for each Treatment Period (Days 1, 8 and 15) and 24-hours post-dose for each Treatment Period (Days 2, 9 and 16)."}, {"measure": "Change From Period Baseline in Peak Percent Predicted Forced Expiratory Volume in 1 Second (FEV1)", "description": "Peak FEV1 was defined as the peak FEV1 up to 4 hours post-dose. The FEV1 percent predicted expresses FEV1 as a percentage of the \"predicted values\" for participants of similar characteristics (height, age, sex, and sometimes race and weight). A positive change from baseline in FEV1 % predicted indicates improvement in lung function. Change from baseline in peak FEV1 % predicted was modeled using a linear mixed effect model fitting treatment, sequence and period as fixed factors, patient within sequence as a random factor and pre-dose value as covariate.", "timeFrame": "Days 1, 8 and 15, pre-dose (Baseline) and 5, 15, and 30 minutes, 1, 2, 3, and 4 hours post-dose."}, {"measure": "Change From Period Baseline in Trough Forced Vital Capacity (FVC)", "description": "Vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Trough FVC was measured 24 hours post-dose. Change form baseline in trough FVC was modeled using a linear mixed effect model fitting treatment, sequence and period as fixed factors, patient within sequence as a random factor and pre-dose value as covariate.", "timeFrame": "Pre-dose for each Treatment Period (Days 1, 8 and 15) and 24-hours post-dose for each Treatment Period (Days 2, 9 and 16)."}, {"measure": "Change From Period Baseline in Peak Forced Vital Capacity (FVC)", "description": "Vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Peak FVC was measured up to 4 hours post-dose. Change from baseline in peak FVC was modeled using a linear mixed effect model fitting treatment, sequence and period as fixed factors, patient within sequence as a random factor and pre-dose value as covariate.", "timeFrame": "Days 1, 8 and 15, pre-dose (Baseline) and 5, 15, and 30 minutes, 1, 2, 3, and 4 hours post-dose."}, {"measure": "Change From Period Baseline in Trough FEV1/FVC Ratio", "description": "The forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio represents the proportion of a person's vital capacity that they are able to expire in the first second of an expiration. Trough FEV1/FVC was calculated from measurements taken 24 hours post-dose. Change from baseline in trough FEV1/FVC ratio was modeled using a linear mixed effect model fitting treatment, sequence and period as fixed factors, patient within sequence as a random factor and pre-dose value as covariate.", "timeFrame": "Pre-dose for each Treatment Period (Days 1, 8 and 15) and 24-hours post-dose for each Treatment Period (Days 2, 9 and 16)."}, {"measure": "Change From Period Baseline in Peak FEV1/FVC Ratio", "description": "The forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio represents the proportion of a person's vital capacity that they are able to expire in the first second of an expiration. Peak FEV1/FVC was calculated from spirometry measurements taken up to 4 hours post-dose. Change from baseline in peak FEV1/FVC ratio was modeled using a linear mixed effect model fitting treatment, sequence and period as fixed factors, patient within sequence as a random factor and pre-dose value as covariate.", "timeFrame": "Days 1, 8 and 15, pre-dose (Baseline) and 5, 15, and 30 minutes, 1, 2, 3, and 4 hours post-dose."}, {"measure": "Area Under the Concentration-time Curve From Time 0 to 12 Hours Post-dose for Mometasone Furoate", "timeFrame": "Samples were taken pre-dose and at 15 and 30 minutes and 1, 2, 4, and 12 hours post-dose."}, {"measure": "Area Under the Concentration-time Curve From Time 0 to 24 Hours Post-dose for Mometasone Furoate", "timeFrame": "Samples were taken pre-dose and at 15 and 30 minutes and 1, 2, 4, 12 and 24 hours post-dose."}, {"measure": "Area Under the Concentration-time Curve From Time 0 to 24 Hours Post-dose for Indacaterol", "timeFrame": "Samples were taken pre-dose and at 15 and 30 minutes and 1, 2, 4, 12 and 24 hours post-dose."}, {"measure": "Maximum (Peak) Plasma Concentration (Cmax) of Mometasone Furoate", "timeFrame": "Samples were taken pre-dose and at 15 and 30 minutes and 1, 2, 4, 12 and 24 hours post-dose."}, {"measure": "Maximum (Peak) Plasma Concentration (Cmax) of Indacaterol", "timeFrame": "Samples were taken pre-dose and at 15 and 30 minutes and 1, 2, 4, 12 and 24 hours post-dose."}, {"measure": "Time to Reach Peak or Maximum Concentration Following Drug Administration for Mometasone Furoate", "timeFrame": "Samples were taken pre-dose and at 15 and 30 minutes and 1, 2, 4, 12 and 24 hours post-dose."}, {"measure": "Time to Reach Peak or Maximum Concentration Following Drug Administration for Indacaterol", "timeFrame": "Samples were taken pre-dose and at 15 and 30 minutes and 1, 2, 4, 12 and 24 hours post-dose."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female adult patients aged 18-75 years with persistent asthma\n* Patients with persistent asthma, diagnosed according to the Global Initiative for Asthma guidelines (GINA) and who additionally met the following criteria:\n\n  1. Patients receiving daily treatment with inhaled corticosteroid up to the maximum dose per day indicated in the package leaflet, in a stable regimen for the month prior to Visit 1.\n  2. Patients with a forced expiratory volume in 1 second (FEV1) at Visit 1 of \u2265 50% of the predicted normal value. This criterion for FEV1 had to be demonstrated after a washout period of at least 6 hours during which no short acting \u03b22-agonist had been inhaled, and a minimum of 48 hours for a long acting \u03b22-agonist.\n  3. Patients who demonstrated an increase of \u226512% and \u2265200 mL in FEV1 over their pre-bronchodilator value 30 minutes after inhaling a total of 200 \u03bcg of salbutamol (or albuterol) via metered dose inhaler (MDI) (the reversibility test). Reversibility had to be demonstrated after an appropriate washout period of at least 6 hrs prior to the evaluation for a shortacting \u03b22-agonist. The administration of salbutamol (or albuterol) for the reversibility test was to be within 30 minutes after pre-bronchodilator spirometry. Reversibility had to be demonstrated at Visit 1 or between Visits 1 and 2, in order for patients to be included in the trial.\n  4. For each patient, the smaller value of the Visit 1 FEV1 or the Visit 2 FEV1 pre-dose value had to be at least 85% of the larger value.\n* Body mass index (BMI) between 18 and 32 kg/m\\^2 and weight \\>50 kg.\n* patients using local contraception\n\nExclusion Criteria:\n\n* Pregnant or nursing women\n* Recent use of tobacco or history of smoking \\> 10 pack years\n* Patients diagnosed with chronic obstructive pulmonary disease (COPD)\n* Patients with recent experience of severe asthma attack/exacerbation within 6-months of study start\n* Patients with frequent rescue medication (\\>8 puffs/day for two consecutive days)\n* Clinically relevant laboratory abnormality or a clinically significant condition\n* Active cancer or a history of cancer with less than 5 years disease free survival time\n* History of long QT syndrome or with long QTc interval prior to dosing\n* History of hypersensitivity to the study drugs or to drugs with similar chemical structures\n* Use of certain medications\n* Use of other investigational drugs\n* A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result\n* History of immunodeficiency diseases, including a positive human immumodeficiency virus (HIV) test result.\n* History of drug or alcohol abuse or evidence of such abuse\n\nOther protocol-defined inclusion/exclusion criteria may apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis", "affiliation": "Novartis investigator site", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Novartis Investigator Site", "city": "Poitiers", "zip": "86000", "country": "France", "geoPoint": {"lat": 46.58333, "lon": 0.33333}}, {"facility": "Novartis Investigator Site", "city": "Berlin", "zip": "14050", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Indacaterol/Mometasone - Placebo", "description": "In Treatment Period 1 (Day 1) participants received 2 inhalations of indacaterol maleate 250 \u03bcg/mometasone furoate 200 \u03bcg once a day in the morning via the Twisthaler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of placebo via the Twisthaler device once a day in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 \u03bcg/salmeterol xinafoate 50 \u03bcg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days."}, {"id": "FG001", "title": "Placebo - Indacaterol/Mometasone", "description": "In Treatment Period 1 (Day 1) participants received 2 inhalations of placebo in the morning via the Twisthaler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of indacaterol maleate 250 \u03bcg/mometasone furoate 200 \u03bcg via the Twisthaler device in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 \u03bcg/salmeterol xinafoate 50 \u03bcg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "Pharmacodynamic (PD) Population", "achievements": [{"groupId": "FG000", "comment": "4 patients inadvertently unblinded were not included in PD analysis population.", "numSubjects": "12"}, {"groupId": "FG001", "comment": "3 patients inadvertently unblinded were not included in PD analysis population.", "numSubjects": "12"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Indacaterol/Mometasone - Placebo", "description": "In Treatment Period 1 (Day 1) participants received 2 inhalations of indacaterol maleate 250 \u03bcg/mometasone furoate 200 \u03bcg once a day in the morning via the Twisthaler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of placebo via the Twisthaler device once a day in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 \u03bcg/salmeterol xinafoate 50 \u03bcg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days."}, {"id": "BG001", "title": "Placebo - Indacaterol/Mometasone", "description": "In Treatment Period 1 (Day 1) participants received 2 inhalations of placebo in the morning via the Twisthaler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of indacaterol maleate 250 \u03bcg/mometasone furoate 200 \u03bcg via the Twisthaler device in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 \u03bcg/salmeterol xinafoate 50 \u03bcg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "31"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "39.1", "spread": "11.93"}, {"groupId": "BG001", "value": "41.5", "spread": "7.23"}, {"groupId": "BG002", "value": "40.3", "spread": "9.85"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "15"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "16"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Period Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)", "description": "FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Change from the period baseline to 24 hour post dose trough FEV1 after 1 day of treatment was modeled using a linear mixed effect model fitting treatment, sequence and period as fixed factors, patient within sequence as a random factor and pre-dose FEV1 as covariate.", "populationDescription": "Pharmacodynamic population included all patients randomized that received at least one dose of study drug and completed the first two treatment periods with evaluable data for the primary efficacy variable, and with no major protocol deviations. 7 patients who were inadvertently unblinded by the investigator were excluded from the PD analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "liters", "timeFrame": "Pre-dose for each Treatment Period (Days 1, 8 and 15) and 24-hours post-dose for each Treatment Period (Days 2, 9 and 16).", "groups": [{"id": "OG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the morning."}, {"id": "OG001", "title": "Placebo", "description": "Participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the morning."}, {"id": "OG002", "title": "Fluticasone/Salmeterol", "description": "Participants received fluticasone/salmeterol 250/50 \u03bcg via dry powder inhaler (DPI), one inhalation in the morning and one inhalation the following evening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.27", "lowerLimit": "0.19", "upperLimit": "0.36"}, {"groupId": "OG001", "value": "-0.12", "lowerLimit": "-0.21", "upperLimit": "-0.04"}, {"groupId": "OG002", "value": "0.37", "lowerLimit": "0.28", "upperLimit": "0.47"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The primary hypothesis tested was that the change from period baseline of trough FEV1 for placebo and indacaterol/mometasone was equal. The one-sided alternative was that the increase from period baseline of trough FEV1 for indacaterol/mometasone was higher than for placebo.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "< 0.0001", "pValueComment": "Linear mixed effect model fitting treatment, sequence and period as fixed factors, patient within sequence as a random factor and pre-dose FEV1 as covariate.\n\nA significance level of 5% was used to determine statistical significance.", "statisticalMethod": "1-sided", "paramType": "LS Mean Difference", "paramValue": "0.39", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.28", "ciUpperLimit": "0.51"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)", "description": "FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Peak FEV1 is defined as the peak FEV1 between 0 and 4 hours post-dose. The change from baseline in peak FEV1 was modeled using a linear mixed effect model fitting treatment, sequence and period as fixed factors, patient within sequence as a random factor and pre-dose FEV1 as covariate.", "populationDescription": "Pharmacodynamic population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "liters", "timeFrame": "Days 1, 8 and 15, pre-dose (Baseline) and 5, 15, and 30 minutes, 1, 2, 3, and 4 hours post-dose.", "groups": [{"id": "OG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the morning."}, {"id": "OG001", "title": "Placebo", "description": "Participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the morning."}, {"id": "OG002", "title": "Fluticasone/Salmeterol", "description": "Participants received fluticasone/salmeterol 250/50 \u03bcg via dry powder inhaler (DPI), one inhalation in the morning and one inhalation the following evening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.64", "lowerLimit": "0.55", "upperLimit": "0.73"}, {"groupId": "OG001", "value": "0.26", "lowerLimit": "0.17", "upperLimit": "0.34"}, {"groupId": "OG002", "value": "0.62", "lowerLimit": "0.54", "upperLimit": "0.71"}]}]}]}, {"type": "SECONDARY", "title": "Change From Period Baseline in Trough Percent Predicted Forced Expiratory Volume in 1 Second (FEV1)", "description": "Trough FEV1 was measured 24 hours post-dose. The FEV1 percent predicted expresses FEV1 as a percentage of the \"predicted values\" for participants of similar characteristics (height, age, sex, and sometimes race and weight). A positive change from baseline in FEV1 % predicted indicates improvement in lung function. Change from baseline in trough FEV1 % predicted was modeled using a linear mixed effect model fitting treatment, sequence and period as fixed factors, patient within sequence as a random factor and pre-dose value as covariate.", "populationDescription": "Pharmacodynamic population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Percent of predicted", "timeFrame": "Pre-dose for each Treatment Period (Days 1, 8 and 15) and 24-hours post-dose for each Treatment Period (Days 2, 9 and 16).", "groups": [{"id": "OG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the morning."}, {"id": "OG001", "title": "Placebo", "description": "Participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the morning."}, {"id": "OG002", "title": "Fluticasone/Salmeterol", "description": "Participants received fluticasone/salmeterol 250/50 \u03bcg via dry powder inhaler (DPI), one inhalation in the morning and one inhalation the following evening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.95", "lowerLimit": "4.68", "upperLimit": "9.22"}, {"groupId": "OG001", "value": "-2.87", "lowerLimit": "-5.14", "upperLimit": "-0.59"}, {"groupId": "OG002", "value": "9.85", "lowerLimit": "7.58", "upperLimit": "12.12"}]}]}]}, {"type": "SECONDARY", "title": "Change From Period Baseline in Peak Percent Predicted Forced Expiratory Volume in 1 Second (FEV1)", "description": "Peak FEV1 was defined as the peak FEV1 up to 4 hours post-dose. The FEV1 percent predicted expresses FEV1 as a percentage of the \"predicted values\" for participants of similar characteristics (height, age, sex, and sometimes race and weight). A positive change from baseline in FEV1 % predicted indicates improvement in lung function. Change from baseline in peak FEV1 % predicted was modeled using a linear mixed effect model fitting treatment, sequence and period as fixed factors, patient within sequence as a random factor and pre-dose value as covariate.", "populationDescription": "Pharmacodynamic population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Percent of predicted", "timeFrame": "Days 1, 8 and 15, pre-dose (Baseline) and 5, 15, and 30 minutes, 1, 2, 3, and 4 hours post-dose.", "groups": [{"id": "OG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the morning."}, {"id": "OG001", "title": "Placebo", "description": "Participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the morning."}, {"id": "OG002", "title": "Fluticasone/Salmeterol", "description": "Participants received fluticasone/salmeterol 250/50 \u03bcg via dry powder inhaler (DPI), one inhalation in the morning and one inhalation the following evening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "16.27", "lowerLimit": "14.24", "upperLimit": "18.29"}, {"groupId": "OG001", "value": "6.85", "lowerLimit": "4.83", "upperLimit": "8.88"}, {"groupId": "OG002", "value": "16.49", "lowerLimit": "14.47", "upperLimit": "18.51"}]}]}]}, {"type": "SECONDARY", "title": "Change From Period Baseline in Trough Forced Vital Capacity (FVC)", "description": "Vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Trough FVC was measured 24 hours post-dose. Change form baseline in trough FVC was modeled using a linear mixed effect model fitting treatment, sequence and period as fixed factors, patient within sequence as a random factor and pre-dose value as covariate.", "populationDescription": "Pharmacodynamic population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "liters", "timeFrame": "Pre-dose for each Treatment Period (Days 1, 8 and 15) and 24-hours post-dose for each Treatment Period (Days 2, 9 and 16).", "groups": [{"id": "OG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the morning."}, {"id": "OG001", "title": "Placebo", "description": "Participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the morning."}, {"id": "OG002", "title": "Fluticasone/Salmeterol", "description": "Participants received fluticasone/salmeterol 250/50 \u03bcg via dry powder inhaler (DPI), one inhalation in the morning and one inhalation the following evening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.22", "lowerLimit": "0.13", "upperLimit": "0.31"}, {"groupId": "OG001", "value": "-0.14", "lowerLimit": "-0.23", "upperLimit": "-0.05"}, {"groupId": "OG002", "value": "0.17", "lowerLimit": "0.08", "upperLimit": "0.27"}]}]}]}, {"type": "SECONDARY", "title": "Change From Period Baseline in Peak Forced Vital Capacity (FVC)", "description": "Vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Peak FVC was measured up to 4 hours post-dose. Change from baseline in peak FVC was modeled using a linear mixed effect model fitting treatment, sequence and period as fixed factors, patient within sequence as a random factor and pre-dose value as covariate.", "populationDescription": "Pharmacodynamic population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "liters", "timeFrame": "Days 1, 8 and 15, pre-dose (Baseline) and 5, 15, and 30 minutes, 1, 2, 3, and 4 hours post-dose.", "groups": [{"id": "OG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the morning."}, {"id": "OG001", "title": "Placebo", "description": "Participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the morning."}, {"id": "OG002", "title": "Fluticasone/Salmeterol", "description": "Participants received fluticasone/salmeterol 250/50 \u03bcg via dry powder inhaler (DPI), one inhalation in the morning and one inhalation the following evening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.47", "lowerLimit": "0.38", "upperLimit": "0.55"}, {"groupId": "OG001", "value": "0.20", "lowerLimit": "0.12", "upperLimit": "0.29"}, {"groupId": "OG002", "value": "0.35", "lowerLimit": "0.27", "upperLimit": "0.44"}]}]}]}, {"type": "SECONDARY", "title": "Change From Period Baseline in Trough FEV1/FVC Ratio", "description": "The forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio represents the proportion of a person's vital capacity that they are able to expire in the first second of an expiration. Trough FEV1/FVC was calculated from measurements taken 24 hours post-dose. Change from baseline in trough FEV1/FVC ratio was modeled using a linear mixed effect model fitting treatment, sequence and period as fixed factors, patient within sequence as a random factor and pre-dose value as covariate.", "populationDescription": "Pharmacodynamic population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "ratio", "timeFrame": "Pre-dose for each Treatment Period (Days 1, 8 and 15) and 24-hours post-dose for each Treatment Period (Days 2, 9 and 16).", "groups": [{"id": "OG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the morning."}, {"id": "OG001", "title": "Placebo", "description": "Participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the morning."}, {"id": "OG002", "title": "Fluticasone/Salmeterol", "description": "Participants received fluticasone/salmeterol 250/50 \u03bcg via dry powder inhaler (DPI), one inhalation in the morning and one inhalation the following evening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.50", "lowerLimit": "2.28", "upperLimit": "2.72"}, {"groupId": "OG001", "value": "2.15", "lowerLimit": "1.93", "upperLimit": "2.37"}, {"groupId": "OG002", "value": "2.65", "lowerLimit": "2.43", "upperLimit": "2.87"}]}]}]}, {"type": "SECONDARY", "title": "Change From Period Baseline in Peak FEV1/FVC Ratio", "description": "The forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio represents the proportion of a person's vital capacity that they are able to expire in the first second of an expiration. Peak FEV1/FVC was calculated from spirometry measurements taken up to 4 hours post-dose. Change from baseline in peak FEV1/FVC ratio was modeled using a linear mixed effect model fitting treatment, sequence and period as fixed factors, patient within sequence as a random factor and pre-dose value as covariate.", "populationDescription": "Pharmacodynamic population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "ratio", "timeFrame": "Days 1, 8 and 15, pre-dose (Baseline) and 5, 15, and 30 minutes, 1, 2, 3, and 4 hours post-dose.", "groups": [{"id": "OG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the morning."}, {"id": "OG001", "title": "Placebo", "description": "Participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the morning."}, {"id": "OG002", "title": "Fluticasone/Salmeterol", "description": "Participants received fluticasone/salmeterol 250/50 \u03bcg via dry powder inhaler (DPI), one inhalation in the morning and one inhalation the following evening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.86", "lowerLimit": "2.63", "upperLimit": "3.10"}, {"groupId": "OG001", "value": "2.53", "lowerLimit": "2.30", "upperLimit": "2.76"}, {"groupId": "OG002", "value": "2.90", "lowerLimit": "2.67", "upperLimit": "3.14"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Concentration-time Curve From Time 0 to 12 Hours Post-dose for Mometasone Furoate", "populationDescription": "All participants with evaluable pharmacokinetic (PK) parameter data were included in the PK data analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg*h/mL", "timeFrame": "Samples were taken pre-dose and at 15 and 30 minutes and 1, 2, 4, and 12 hours post-dose.", "groups": [{"id": "OG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the morning."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "287", "spread": "140"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Concentration-time Curve From Time 0 to 24 Hours Post-dose for Mometasone Furoate", "populationDescription": "All participants with evaluable pharmacokinetic (PK) parameter data were included in the PK data analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg*h/mL", "timeFrame": "Samples were taken pre-dose and at 15 and 30 minutes and 1, 2, 4, 12 and 24 hours post-dose.", "groups": [{"id": "OG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the morning."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "389", "spread": "191"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Concentration-time Curve From Time 0 to 24 Hours Post-dose for Indacaterol", "populationDescription": "All participants with evaluable pharmacokinetic (PK) parameter data were included in the PK data analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg*h/mL", "timeFrame": "Samples were taken pre-dose and at 15 and 30 minutes and 1, 2, 4, 12 and 24 hours post-dose.", "groups": [{"id": "OG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the morning."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1331", "spread": "712"}]}]}]}, {"type": "SECONDARY", "title": "Maximum (Peak) Plasma Concentration (Cmax) of Mometasone Furoate", "populationDescription": "All participants with evaluable pharmacokinetic (PK) parameter data were included in the PK data analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "Samples were taken pre-dose and at 15 and 30 minutes and 1, 2, 4, 12 and 24 hours post-dose.", "groups": [{"id": "OG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the morning."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "47.3", "spread": "20.9"}]}]}]}, {"type": "SECONDARY", "title": "Maximum (Peak) Plasma Concentration (Cmax) of Indacaterol", "populationDescription": "All participants with evaluable pharmacokinetic (PK) parameter data were included in the PK data analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "Samples were taken pre-dose and at 15 and 30 minutes and 1, 2, 4, 12 and 24 hours post-dose.", "groups": [{"id": "OG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the morning."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "289", "spread": "133"}]}]}]}, {"type": "SECONDARY", "title": "Time to Reach Peak or Maximum Concentration Following Drug Administration for Mometasone Furoate", "populationDescription": "All participants with evaluable pharmacokinetic (PK) parameter data were included in the PK data analysis.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hours", "timeFrame": "Samples were taken pre-dose and at 15 and 30 minutes and 1, 2, 4, 12 and 24 hours post-dose.", "groups": [{"id": "OG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the morning."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.05", "lowerLimit": "0.250", "upperLimit": "2.08"}]}]}]}, {"type": "SECONDARY", "title": "Time to Reach Peak or Maximum Concentration Following Drug Administration for Indacaterol", "populationDescription": "All participants with evaluable pharmacokinetic (PK) parameter data were included in the PK data analysis.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hours", "timeFrame": "Samples were taken pre-dose and at 15 and 30 minutes and 1, 2, 4, 12 and 24 hours post-dose.", "groups": [{"id": "OG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the morning."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.325", "lowerLimit": "0.267", "upperLimit": "0.617"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the morning.", "seriousNumAffected": 0, "seriousNumAtRisk": 29, "otherNumAffected": 10, "otherNumAtRisk": 29}, {"id": "EG001", "title": "Placebo", "description": "Participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the morning.", "seriousNumAffected": 0, "seriousNumAtRisk": 28, "otherNumAffected": 6, "otherNumAtRisk": 28}, {"id": "EG002", "title": "Fluticasone/Salmeterol", "description": "Participants received fluticasone/salmeterol 250/50 \u03bcg via dry powder inhaler (DPI), one inhalation in the morning and one inhalation the following evening.", "seriousNumAffected": 0, "seriousNumAtRisk": 26, "otherNumAffected": 2, "otherNumAtRisk": 26}], "otherEvents": [{"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 26}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 26}]}, {"term": "Tongue coated", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 26}]}, {"term": "Catheter site haematoma", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 26}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 26}]}, {"term": "Oral candidiasis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 26}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 26}]}, {"term": "Vulvovaginal mycotic infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 26}]}, {"term": "Neck pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 26}]}, {"term": "Torticollis", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 26}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 28}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 26}]}, {"term": "Restlessness", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 26}]}, {"term": "Premenstrual syndrome", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 26}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 26}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Switzerland"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "D000068656", "term": "Mometasone Furoate"}, {"id": "D000068299", "term": "Salmeterol Xinafoate"}, {"id": "C000030272", "term": "Maleic acid"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M290", "name": "Mometasone Furoate", "asFound": "Tea", "relevance": "HIGH"}, {"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "relevance": "LOW"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Healthy diet", "relevance": "HIGH"}, {"id": "M245808", "name": "Maleic acid", "asFound": "Fast", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}